More tools:Markets·Screener·Research Chat

Gilead Sciences Inc (GILD) Financial Statements

Gilead Sciences Inc
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S6Y1X7
XNAS · usd
130.04▼ 1.36 (-1.04%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$29.7B
Net Income (TTM)$9.2B
EBITDA
Diluted EPS (TTM)
EBITDA Margin44.2%
Net Debt
Trading Information
Previous Close131.40
Day's Range129.42 – 131.21
52-Week Range107.75 – 157.30
Volume5.13M
Avg Volume8.26M
Share Statistics
Shares Outstanding1.2B
Employees17.0K
ExchangeXNAS
Listed1992-01-22

Key questions about Gilead Sciences Inc (GILD)

What is Gilead Sciences Inc's Market Cap?
Gilead Sciences Inc's Market Cap is $161.5B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Enterprise Value?
Gilead Sciences Inc's Enterprise Value is $183.3B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Trailing P/E?
Gilead Sciences Inc's Trailing P/E is 17.5×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Price / Sales?
Gilead Sciences Inc's Price / Sales is 5.4×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EV / Revenue?
Gilead Sciences Inc's EV / Revenue is 6.2×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EV / EBITDA?
Gilead Sciences Inc's EV / EBITDA is 13.9×, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Revenue (TTM)?
Gilead Sciences Inc's Revenue (TTM) is $29.7B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Net Income (TTM)?
Gilead Sciences Inc's Net Income (TTM) is $9.2B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's EBITDA?
Gilead Sciences Inc's EBITDA is $13.1B, based on as-reported figures from SEC (XBRL) filings.
What is Gilead Sciences Inc's Diluted EPS (TTM)?
Gilead Sciences Inc's Diluted EPS (TTM) is 7.42, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenues:
Product sales
YoY growth+5.0%+4.9%-2.3%+2.1%
Royalty, contract and other revenues
Total revenues
Costs and expenses:
Cost of goods sold
Research and development expenses
Acquired in-process research and development expenses
Selling, general and administrative expenses
Total costs and expenses
% of revenue63.0%75.2%60.5%65.3%
Income (loss) from operations
% of revenue37.2%25.1%45.3%35.1%
Interest expense
Other (income) expense, net
Income (loss) before income taxes
Income tax expense (benefit)
Net income (loss)
% of revenue29.1%27.6%41.6%27.8%
Basic earnings per share
Diluted earnings per share
Shares used in basic earnings per share calculation
Shares used in diluted earnings per share calculation